Vanda motion sickness approval comes with ‘broad’ label, says Cantor

Cantor Fitzgerald analyst Olivia Brayer keeps an Overweight rating on Vanda Pharmaceuticals (VNDA) with an $11 price target after the FDA approved Nereus for the prevention of motion sickness. The motion sickness opportunity could add upside to estimates, but the bigger implication is that the approval could have an “important look-through” for Vanda’s GLP-1 nausea program, which begins Phase 3 in 2026, the analyst tells investors in a research note. Cantor views Nereus’ label as “fairly broad.” Vanda has talked about motion sickness as a several hundred million peak sales opportunity, the firm adds.